After meeting all prespecified endpoints at
the interim analysis, what was the median
overall survival (OS) in the TUKYSA arm at
follow-up analysis?

For patients with brain metastases, what
was the median OS of patients in the TUKYSA
arm vs control arm at follow-up?

TUKYSA reduced the risk of developing a
new brain lesion at the site of first progression
or death by how much for all patients with or
without brain metastases?

In order to manage adverse reactions,
some patients may require dose modifications.
Which of the following are true regarding
modifying the TUKYSA dose?